bluebird bio announces data from HGB-205 clinical study bluebird bio on Saturday released initial clinical data from its HGB-205 clinical study of its LentiGlobin BB305 product candidate in beta-thalassemia major subjects. The company said the clinical update provided on two subjects treated in the prior LG001 Study using the prior lentiviral HPV569 product candidate; Subject 3 remains blood transfusion independent 72 months after being transplanted with the lentiviral HPV569 product candidate; Subjects 3 and 4 are producing 2.7 g/dL and 0.4 g/dL of therapeutic beta A-T87Q-globin post-transplant, respectively; No drug product related adverse events were reported in the LG001 Study. The company sees reporting additional data from the HGB-205 Study and from our ongoing Northstar Study in late 2014.
bluebird bio price target raised to $119 from $112 at Piper Jaffray Piper Jaffray raised its price target for bluebird bio to $119 following the company's Q4 results and reiterates an Overweight rating on the name. Piper sees 2015 as a "big year" for bluebird with preliminary sickle cell data.